{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:42:57Z","timestamp":1780389777278,"version":"3.54.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T00:00:00Z","timestamp":1573948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81725020"],"award-info":[{"award-number":["81725020"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872742"],"award-info":[{"award-number":["81872742"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003395","name":"Shanghai Municipal Education Commission","doi-asserted-by":"publisher","award":["2019-01-07-00-07-E00073"],"award-info":[{"award-number":["2019-01-07-00-07-E00073"]}],"id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.apsb.2019.11.011","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T12:20:55Z","timestamp":1574338855000},"page":"1294-1308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity"],"prefix":"10.1016","volume":"10","author":[{"given":"Yahui","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanchao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunquan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2019.11.011_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cell.2011.03.026","article-title":"The evolving war on cancer","volume":"145","author":"Haber","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2019.11.011_bib2","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1158\/2159-8290.CD-12-0400","article-title":"Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: six degrees of separation","volume":"2","author":"Trusolino","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2019.11.011_bib3","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrd2089","article-title":"Strategies for optimizing combinations of molecularly targeted anticancer agents","volume":"5","author":"Dancey","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2019.11.011_bib4","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1021\/jm400856t","article-title":"Polypharmacology\u2014foe or friend?","volume":"56","author":"Peters","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2019.11.011_bib5","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1021\/jm5006463","article-title":"Polypharmacology: challenges and opportunities in drug discovery","volume":"57","author":"Anighoro","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2019.11.011_bib6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S1359-6446(04)03163-0","article-title":"From magic bullets to designed multiple ligands","volume":"9","author":"Morphy","year":"2004","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2019.11.011_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40169-017-0181-2","article-title":"A perspective on multi-target drug discovery and design for complex diseases","volume":"7","author":"Ramsay","year":"2018","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.apsb.2019.11.011_bib8","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/nrc3130","article-title":"A decade of exploring the cancer epigenome\u2012biological and translational implications","volume":"11","author":"Baylin","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2019.11.011_bib9","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","article-title":"The epigenomics of cancer","volume":"128","author":"Jones","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2019.11.011_bib10","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/nbt.1685","article-title":"Epigenetic modifications and human disease","volume":"28","author":"Portela","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2019.11.011_bib11","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nbt.1678","article-title":"Epigenetic modifications as therapeutic targets","volume":"28","author":"Kelly","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2019.11.011_bib12","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2213-0802-1-6","article-title":"Oncogenic driver mutations in lung cancer","volume":"1","author":"Luo","year":"2013","journal-title":"Transl Respir Med"},{"key":"10.1016\/j.apsb.2019.11.011_bib13","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/phar.1408","article-title":"Epigenetics and oncology","volume":"34","author":"Mummaneni","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.apsb.2019.11.011_bib14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","article-title":"The role of histone deacetylases (HDACs) in human cancer","volume":"1","author":"Ropero","year":"2007","journal-title":"Mol Oncol"},{"key":"10.1016\/j.apsb.2019.11.011_bib15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2019.11.011_bib16","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2019.11.011_bib17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nm1161","article-title":"Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells","volume":"11","author":"Nebbioso","year":"2005","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2019.11.011_bib18","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1158\/1078-0432.CCR-05-1132","article-title":"Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589","volume":"12","author":"Qian","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2019.11.011_bib19","doi-asserted-by":"crossref","first-page":"11298","DOI":"10.1158\/0008-5472.CAN-06-0049","article-title":"Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer","volume":"66","author":"Geng","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2019.11.011_bib20","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"The Oncologist"},{"key":"10.1016\/j.apsb.2019.11.011_bib21","first-page":"47","article-title":"Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents","volume":"7","author":"Ververis","year":"2013","journal-title":"Biologics"},{"key":"10.1016\/j.apsb.2019.11.011_bib22","first-page":"269","article-title":"Panobinostat for the treatment of multiple myeloma: the evidence to date","volume":"6","author":"Bailey","year":"2015","journal-title":"J Blood Med"},{"key":"10.1016\/j.apsb.2019.11.011_bib23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bioorg.2016.05.005","article-title":"Inhibitors of histone deacetylase as antitumor agents: a critical review","volume":"67","author":"Manal","year":"2016","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.apsb.2019.11.011_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2217\/fon.11.2","article-title":"Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer","volume":"7","author":"Thurn","year":"2011","journal-title":"Future Oncol"},{"key":"10.1016\/j.apsb.2019.11.011_bib25","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.bcp.2011.11.010","article-title":"Sensitization of tumor cells by targeting histone deacetylases","volume":"83","author":"Perego","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2019.11.011_bib26","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1002\/med.21505","article-title":"Chimeric HDAC inhibitors: comprehensive review on the HDAC-based strategies developed to combat cancer","volume":"38","author":"Hesham","year":"2018","journal-title":"Med Res Rev"},{"key":"10.1016\/j.apsb.2019.11.011_bib27","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/cmdc.201500394","article-title":"Multitarget drugs: an epigenetic epiphany","volume":"11","author":"Ganesan","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.apsb.2019.11.011_bib28","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1074\/jbc.C000824200","article-title":"Deacetylase activity associates with topoisomerase II and is necessary for etoposide-induced apoptosis","volume":"276","author":"Johnson","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2019.11.011_bib29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/jcb.20045","article-title":"Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid","volume":"92","author":"Marchion","year":"2004","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.apsb.2019.11.011_bib30","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.3390\/molecules14051852","article-title":"Evodiamine: a novel anti-cancer alkaloid from Evodia rutaecarpa","volume":"14","author":"Jiang","year":"2009","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2019.11.011_bib31","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3390\/molecules18021826","article-title":"Pharmacological actions of multi-target-directed evodiamine","volume":"18","author":"Yu","year":"2013","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2019.11.011_bib32","doi-asserted-by":"crossref","first-page":"7521","DOI":"10.1021\/jm100387d","article-title":"Selection of evodiamine as a novel topoisomerase I inhibitor by structure-based virtual screening and hit optimization of evodiamine derivatives as antitumor agents","volume":"53","author":"Dong","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2019.11.011_bib33","doi-asserted-by":"crossref","first-page":"7593","DOI":"10.1021\/jm300605m","article-title":"New tricks for an old natural product: discovery of highly potent evodiamine derivatives as novel antitumor agents by systemic structure\u2013activity relationship analysis and biological evaluations","volume":"55","author":"Dong","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2019.11.011_bib34","doi-asserted-by":"crossref","first-page":"6678","DOI":"10.1021\/acs.jmedchem.5b00910","article-title":"Scaffold diversity inspired by the natural product evodiamine: discovery of highly potent and multitargeting antitumor agents","volume":"58","author":"Wang","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2019.11.011_bib35","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.apsb.2018.08.003","article-title":"Novel fluorescent probes of 10-hydroxyevodiamine: autophagy and apoptosis-inducing anticancer mechanisms","volume":"9","author":"Chen","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2019.11.011_bib36","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1021\/ml500327q","article-title":"Discovery of novel multiacting topoisomerase I\/II and histone deacetylase Inhibitors","volume":"6","author":"He","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.apsb.2019.11.011_bib37","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1111\/bph.12320","article-title":"Effect of chirality and lipophilicity in the functional activity of evodiamine and its analogues at TRPV1 channels","volume":"171","author":"de Petrocellis","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.apsb.2019.11.011_bib38","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.1016\/j.bmc.2013.09.030","article-title":"Quinazolinecarboline alkaloid evodiamine as scaffold for targeting topoisomerase I and sirtuins","volume":"21","author":"Christodoulou","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2019.11.011_bib39","series-title":"Wu KK, inventors. 5-Methoxytryptophan and its derivatives and uses thereof","author":"Kuo","year":"2016"},{"key":"10.1016\/j.apsb.2019.11.011_bib40","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nchembio.313","article-title":"Chemical phylogenetics of histone deacetylases","volume":"6","author":"Bradner","year":"2010","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2019.11.011_bib41","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","article-title":"DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139","volume":"273","author":"Rogakou","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2019.11.011_bib42","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.molcel.2013.05.020","article-title":"Class I HDACs share a common mechanism of regulation by inositol phosphates","volume":"51","author":"Millard","year":"2013","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2019.11.011_bib43","doi-asserted-by":"crossref","first-page":"10920","DOI":"10.1093\/nar\/gkx806","article-title":"Producing irreversible topoisomerase II-mediated DNA breaks by site-specific Pt(II)-methionine coordination chemistry","volume":"45","author":"Wang","year":"2017","journal-title":"Nucleic Acids Res"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383519310160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383519310160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:43:54Z","timestamp":1761929034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383519310160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S2211383519310160"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2019.11.011","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2019.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}